Cover Image
市場調查報告書

急性缺血性腦中風的開發平台分析

Acute Ischemic Stroke - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232801
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
Back to Top
急性缺血性腦中風的開發平台分析 Acute Ischemic Stroke - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 130 Pages
簡介

急性缺血性腦中風是由於血管閉塞造成血流停留,以致週邊腦組織的缺氧而發病,由於氧氣不足,週邊腦細胞開始壞死。症狀有四肢或半身麻痺和知覺異常,肌肉無力,喪失部分視覺與聽覺,不明瞭發音,複視,眩暈等。

本報告涵括全球急性缺血性腦中風治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品評估等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

急性缺血性腦中風概要

治療藥的開發

  • 急性缺血性腦中風開發中產品:概要
  • 急性缺血性腦中風開發中產品:比較分析

急性缺血性腦中風:正在開發的治療藥:各企業

急性缺血性腦中風:正在開發的治療藥:大學·研究機關別

急性缺血性腦中風:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

急性缺血性腦中風:開發中的產品:各企業

急性缺血性腦中風:開發中的產品:大學·研究機關別

急性缺血性腦中風:治療藥開發作的企業

  • AB Science SA
  • AstraZeneca Plc
  • Biogen, Inc.
  • D-Pharm Ltd.
  • 第一三共
  • DiaMedica Inc.
  • Digna Biotech, S.L.
  • Glucox Biotech AB
  • Grifols, S.A.
  • Lumosa Therapeutics Co., Ltd.
  • 田邊三菱製藥
  • Pharmicell Co., Ltd.
  • PhytoHealth Corporation
  • Remedy Pharmaceuticals, Inc.
  • Simcere Pharmaceutical Group
  • Stemedica Cell Technologies, Inc.
  • ZZ Biotech, LLC

急性缺血性腦中風:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 3K3A-APC
    • 產品概要
    • 作用機制
    • R&D的進展
  • Cerecellgram-Stroke
  • DB-017
  • DM-199
  • DS-1040
  • glyburide
  • HBN-1
  • 人血漿素
  • LT-3001
  • masitinib
  • 間充織幹細胞
  • MP-124
  • natalizumab
  • Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke
  • PHN-014
  • 重組的血漿素
  • SIM-071201
  • 急性缺血性腦中風NOX-4阻礙小分子1
  • 急性缺血性腦中風NOX-4阻礙小分子2
  • THR-18
  • ticagrelor
  • TS-01

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8495IDB

Summary

Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H2 2016', provides an overview of the Acute Ischemic Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
  • The report reviews pipeline therapeutics for Acute Ischemic Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Ischemic Stroke therapeutics and enlists all their major and minor projects
  • The report assesses Acute Ischemic Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Ischemic Stroke

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Ischemic Stroke Overview
  • Therapeutics Development
    • Pipeline Products for Acute Ischemic Stroke - Overview
  • Acute Ischemic Stroke - Therapeutics under Development by Companies
  • Acute Ischemic Stroke - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acute Ischemic Stroke - Products under Development by Companies
  • Acute Ischemic Stroke - Companies Involved in Therapeutics Development
    • AB Science SA
    • AstraZeneca Plc
    • Biogen Inc
    • D-Pharm Ltd.
    • Daiichi Sankyo Company, Limited
    • DiaMedica Inc.
    • Digna Biotech, S.L.
    • Glucox Biotech AB
    • Jeil Pharmaceutical Co., Ltd.
    • Lumosa Therapeutics Co., Ltd.
    • Mitsubishi Tanabe Pharma Corporation
    • Pharmicell Co., Ltd.
    • PhytoHealth Corporation
    • Remedy Pharmaceuticals, Inc.
    • Saneron CCEL Therapeutics, Inc.
    • Simcere Pharmaceutical Group
    • Stemedica Cell Technologies, Inc.
  • Acute Ischemic Stroke - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 3K3A-APC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AB-022 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ApTLR-4FT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellgram-IS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DB-017 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DM-199 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-1040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glyburide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HBI-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HBN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JPI-289 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-3001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-124 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • natalizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neu-2000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PHN-014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rejuveinix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SIM-071201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THR-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ticagrelor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TMS-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acute Ischemic Stroke - Dormant Projects
  • Acute Ischemic Stroke - Discontinued Products
  • Acute Ischemic Stroke - Product Development Milestones
    • Featured News & Press Releases
      • Sep 12, 2016: DiaMedica Announces Regulatory Clearance to Initiate Bridging Clinical Trial for DM199
      • Jun 14, 2016: DiaMedica Announces U.S. Composition of Matter Patent for DM199
      • Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia
      • Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial
      • Nov 04, 2015: DiaMedica Provides Corporate Update
      • Oct 09, 2015: Remedy Pharmaceuticals' Drug CIRARA™ Cut Death Rates from Severe Stroke by More Than Half
      • Sep 29, 2015: Remedy Pharmaceuticals Announces Phase 2 Severe Stroke Study Results to Be Presented at Neurocritical Care Annual Meeting
      • Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference
      • Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA
      • Nov 04, 2014: D-Pharm Reports First Results From its Phase 2 Clinical Study of THR-18 In Acute Stroke Patients Treated with tPA
      • Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA
      • Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA
      • Apr 22, 2014: ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures
      • Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients
      • Jan 21, 2014: D-Pharm completes recruitment of patients into the first dosage tier of its Phase 2 study with THR-18 in acute stroke patients treated with tPA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Ischemic Stroke, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Acute Ischemic Stroke - Pipeline by AB Science SA, H2 2016
  • Acute Ischemic Stroke - Pipeline by AstraZeneca Plc, H2 2016
  • Acute Ischemic Stroke - Pipeline by Biogen Inc, H2 2016
  • Acute Ischemic Stroke - Pipeline by D-Pharm Ltd., H2 2016
  • Acute Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Acute Ischemic Stroke - Pipeline by DiaMedica Inc., H2 2016
  • Acute Ischemic Stroke - Pipeline by Digna Biotech, S.L., H2 2016
  • Acute Ischemic Stroke - Pipeline by Glucox Biotech AB, H2 2016
  • Acute Ischemic Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
  • Acute Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2016
  • Acute Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Acute Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H2 2016
  • Acute Ischemic Stroke - Pipeline by PhytoHealth Corporation, H2 2016
  • Acute Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2016
  • Acute Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2016
  • Acute Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2016
  • Acute Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acute Ischemic Stroke - Dormant Projects, H2 2016
  • Acute Ischemic Stroke - Dormant Projects (Contd..1), H2 2016
  • Acute Ischemic Stroke - Dormant Projects (Contd..2), H2 2016
  • Acute Ischemic Stroke - Discontinued Products, H2 2016
  • Acute Ischemic Stroke - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Acute Ischemic Stroke, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top